JP2024520307A5 - - Google Patents
Info
- Publication number
- JP2024520307A5 JP2024520307A5 JP2023570225A JP2023570225A JP2024520307A5 JP 2024520307 A5 JP2024520307 A5 JP 2024520307A5 JP 2023570225 A JP2023570225 A JP 2023570225A JP 2023570225 A JP2023570225 A JP 2023570225A JP 2024520307 A5 JP2024520307 A5 JP 2024520307A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- administration unit
- pharmaceutical
- pharmaceutical composition
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21175623 | 2021-05-25 | ||
| EP21175623.4 | 2021-05-25 | ||
| PCT/EP2022/063887 WO2022248401A1 (en) | 2021-05-25 | 2022-05-23 | A plurality of tasquinimod particles and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024520307A JP2024520307A (ja) | 2024-05-24 |
| JP2024520307A5 true JP2024520307A5 (https=) | 2025-05-21 |
Family
ID=76098832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023570225A Pending JP2024520307A (ja) | 2021-05-25 | 2022-05-23 | 複数のタスキニモド粒子およびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US12485095B2 (https=) |
| EP (1) | EP4346773B1 (https=) |
| JP (1) | JP2024520307A (https=) |
| KR (1) | KR20240012436A (https=) |
| CN (1) | CN117295492A (https=) |
| AU (1) | AU2022281056A1 (https=) |
| BR (1) | BR112023023715A2 (https=) |
| CA (1) | CA3218977A1 (https=) |
| ES (1) | ES3048983T3 (https=) |
| IL (1) | IL308542A (https=) |
| MX (1) | MX2023013301A (https=) |
| PL (1) | PL4346773T3 (https=) |
| WO (1) | WO2022248401A1 (https=) |
| ZA (1) | ZA202311594B (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025228998A1 (en) * | 2024-04-30 | 2025-11-06 | Institut National de la Santé et de la Recherche Médicale | Use of hdac4 inhibitors for the treatment of melanoma |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9801474D0 (sv) | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
| SE9802549D0 (sv) | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
| SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Active Biotech Ab | Malignant tumors |
| SE0201778D0 (sv) | 2002-06-12 | 2002-06-12 | Active Biotech Ab | Process for the manufacture of quinoline derivatives |
| SG186430A1 (en) | 2010-07-09 | 2013-01-30 | Active Biotech Ab | Method for manufacturing of quinoline-3-carboxamides |
| EP2537517A1 (en) | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
| US10213422B2 (en) | 2014-04-14 | 2019-02-26 | Yale University | Compositions and methods of inhibiting histone deacetylases |
| JP6647287B2 (ja) | 2014-09-23 | 2020-02-14 | アクティブ バイオテック エイビー | 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド |
| MX379401B (es) | 2014-11-19 | 2025-03-11 | Active Biotech Ab | Carboxamidas de quinolina para usarse en el tratamiento de leucemia. |
| EP3067062A1 (en) | 2015-03-13 | 2016-09-14 | Ipsen Pharma S.A.S. | Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament |
| WO2018105943A1 (ko) | 2016-12-07 | 2018-06-14 | 순천향대학교 산학협력단 | 폐섬유증 또는 천식의 치료 또는 완화용 약학 조성물 |
| BR112023000892A2 (pt) | 2020-07-23 | 2023-02-07 | Univ Erasmus Med Ct Rotterdam | Inibidor de uma proteína s100 para uso na prevenção ou tratamento de uma neoplasia mieloproliferativa, agente e método para identificar um indivíduo que sofre de uma neoplasia mieloproliferativa, e, métodos para identificar um indivíduo em risco de desenvolver mielofibrose e que se beneficie de um tratamento com um inibidor |
| ES3057099T3 (en) | 2021-01-18 | 2026-02-26 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
-
2022
- 2022-05-23 PL PL22730773.3T patent/PL4346773T3/pl unknown
- 2022-05-23 CN CN202280034543.8A patent/CN117295492A/zh active Pending
- 2022-05-23 WO PCT/EP2022/063887 patent/WO2022248401A1/en not_active Ceased
- 2022-05-23 JP JP2023570225A patent/JP2024520307A/ja active Pending
- 2022-05-23 IL IL308542A patent/IL308542A/en unknown
- 2022-05-23 US US18/289,738 patent/US12485095B2/en active Active
- 2022-05-23 ES ES22730773T patent/ES3048983T3/es active Active
- 2022-05-23 EP EP22730773.3A patent/EP4346773B1/en active Active
- 2022-05-23 BR BR112023023715A patent/BR112023023715A2/pt unknown
- 2022-05-23 KR KR1020237042849A patent/KR20240012436A/ko active Pending
- 2022-05-23 CA CA3218977A patent/CA3218977A1/en active Pending
- 2022-05-23 AU AU2022281056A patent/AU2022281056A1/en active Pending
- 2022-05-23 MX MX2023013301A patent/MX2023013301A/es unknown
-
2023
- 2023-12-18 ZA ZA2023/11594A patent/ZA202311594B/en unknown
-
2025
- 2025-11-24 US US19/399,224 patent/US20260076908A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025060813A5 (https=) | ||
| JP6757959B2 (ja) | 抗がん剤 | |
| TWI841481B (zh) | 乳酸鈣組成物及使用方法 | |
| RU2738934C2 (ru) | Способы лечения рака с использованием апилимода | |
| JP2020535158A (ja) | ニラパリブ処方物 | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| EP2575783B1 (en) | Methods and compositions for oral pharmaceutical therapy | |
| JP2003533485A5 (https=) | ||
| CN105705148A (zh) | 使用普那布林和紫杉烷的组合的癌症疗法 | |
| JP2019509253A5 (https=) | ||
| WO2015187194A1 (en) | Use of paclitaxel particles | |
| JP2012522837A5 (https=) | ||
| JP2019510785A5 (https=) | ||
| JP2023546362A5 (https=) | ||
| KR20210005714A (ko) | 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법 | |
| JP2019501185A (ja) | 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット | |
| Kobayashi et al. | Pharmacokinetic study of weekly administration dose of paclitaxel in patients with advanced or recurrent gastric cancer in Japan | |
| JP2021505669A5 (https=) | ||
| JP2024520307A5 (https=) | ||
| TW201821107A (zh) | 一種ｖｅｇｆｒ抑制劑與ｐａｒｐ抑制劑聯合在製備治療胃癌的藥物中的用途 | |
| JP2010504307A5 (https=) | ||
| CA2925960A1 (en) | Pharmaceutical composition comprising capecitabine and cyclophosphamide | |
| JP2010106019A (ja) | リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤 | |
| CN105025883A (zh) | 右哌甲酯或其盐的调节释放的药物组合物 | |
| CN111787922A (zh) | 用于治疗肝细胞癌的组合疗法 |